333361-49-2

Basic information

• Product Name: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone
• Synonyms: (5-broMo-2-chloro-phenyl)-(4-Methoxyl-phenyl)-Methanone;(5-Bromo-2-chlorophenyl)(4-methoxyphenyl)-methanone
• CAS NO: 333361-49-2
• Molecular Formula: C₁₄H₁₀BrClO₂
• Molecular Weight: 325.585
• Mol File: 333361-49-2.mol
• Article Data: 30

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane; Ethyl Acetate
• CAS DataBase Reference: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone(333361-49-2)
• EPA Substance Registry System: (5-broMo-2-chloro-phenyl)-(4-ethoxy-phenyl)-Methanone(333361-49-2)

Safety Data

• Hazardous Substances Data: 333361-49-2(Hazardous Substances Data)

Usage

Uses

(5-Bromo-2-chlorophenyl)(4-methoxyphenyl)methanone is an intermediate in synthesizing Dapagliflozin-D5 (D185372), a labelled analogue of Dapagliflozin (D185370), which is a selective sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption and is used to treat patients with type 2 diabetes.

Upstream product

• 100-66-3 methoxybenzene 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 

Downstream Products

• 912917-83-0 (3R,4S,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol 

Relevant articles and documents

Combined catalyst for use in specific Friedel-Crafts reactions

The invention provides an application of a ferric trichloride and indium trichloride combined catalyst in a specific Friedel-Crafts reaction, more specifically, the invention provides an application of a ferric trichloride and indium trichloride combined Lewis acid catalyst in preparation of a key intermediate of empagliflozin, dapagliflozin and canagliflozin drugs. Compared with the prior art, the ferric trichloride and indium trichloride combined catalyst provided by the invention can greatly reduce the use of inorganic salt in the preparation process of the key intermediate of the empagliflozin, dapagliflozin and canagliflozin drugs, and obviously reduce the emission of waste water, waste gases and waste residues; and the ferric trichloride and indium trichloride combined catalyst can significantly improve the selectivity of para-position products in the preparation process of the key intermediate of the empagliflozin, dapagliflozin and canagliflozin drugs, can remarkably improve the quality and the yield of a target product, and remarkably reduce the process cost.

GLUCOPYRANOSE DERIVATIVES USEFUL AS SGLT2 INHIBITORS

The present invention is directed to glucopyranose derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

Carbon glucoside sodium glucose transport protein body 2 inhibitor

The invention relates to a carbon glucoside sodium glucose transport protein body 2 inhibitor, a preparation method and an application of the inhibitor. The carbon glucoside sodium glucose transport protein body 2 inhibitor has a structure as shown in general formula (I) as shown in the specification.